Stockscreener 앱 받기
1.245
35.59%
0.3305
전일 마감가:
$0.9145
열려 있는:
$0.95005
하루 거래량:
11.41M
Relative Volume:
7.85
시가총액:
$230.68M
수익:
-
순이익/손실:
$-222.39M
주가수익비율:
-0.9383
EPS:
-1.3268
순현금흐름:
$-193.40M
1주 성능:
-24.85%
1개월 성능:
-32.61%
6개월 성능:
-32.97%
1년 성능:
+43.58%
1일 변동 폭
$0.92
$1.27
1주일 범위
$0.8302
$1.84
52주 변동 폭
$0.7158
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
명칭
Neumora Therapeutics Inc
전화
(857) 760-0900
주소
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.245 | 169.44M | 0 | -222.39M | -193.40M | -1.3268 |
VRTX
Vertex Pharmaceuticals Inc
|
449.83 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.34 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
880.02 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.98 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.18 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2026-01-12 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-09-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-04-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-03-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-10-10 | 개시 | BofA Securities | Buy |
| 2023-10-10 | 개시 | Guggenheim | Buy |
| 2023-10-10 | 개시 | JP Morgan | Overweight |
| 2023-10-10 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-10 | 개시 | Stifel | Buy |
| 2023-10-10 | 개시 | William Blair | Outperform |
모두보기
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
Needham cuts Neumora stock price target on navacaprant discontinuation By Investing.com - Investing.com Canada
Neumora stock price target cut to $7 on failed trial, H.C. Wainwright maintains buy - Investing.com Canada
Neumora bins depression drug after Phase III failures - The Pharma Letter
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials - Asianet Newsable
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Benzinga
NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc. - GlobeNewswire
Neumora plummets as phase 3 navacaprant data misses key goal - MSN
Neumora shifts focus to Alzheimer's and obesity drugs after navacaprant setback - The Business Journals
Neumora scraps depression drug development after repeated trial failures - Reuters
Neumora discards depression asset, lays off staffers after pair of late-stage flops - BioSpace
Neumora Therapeutics Discontinues Navacaprant After Phase 3 Failure, Advances Alzheimer’s and Schizophrenia Pipeline - Minichart
Neumora stock plunges after phase 3 trial failure By Investing.com - Investing.com South Africa
Navacaprant fails Phase 3 trials; Neumora halts its development, focusing on other drug candidates. - Pluang
Neumora Ends Depression Drug Programme and Announces Workforce Reduction (NMRA) - Yahoo Finance
Neumora pulls plug off depression drug after trial failures, cut jobs - Investing.com Canada
Neumora Ends Navacaprant After Phase 3 Trial Failure - TipRanks
Neumora discontinues navacaprant after phase 3 trial failures - Investing.com
Neumora discontinues navacaprant after phase 3 trial failures By Investing.com - Investing.com Canada
Neumora Therapeutics scraps depression drug after two late-stage trial failures - TradingView
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update - The Manila Times
Neumora scraps depression drug, cuts 35% of staff, refocuses pipeline - Stock Titan
CRNX,NMRA Volatility & Greeks - Finviz
Neumora Therapeutics (NMRA) Slips Near Key Support; Oversold Conditions LoomMonthly Profile - newsline.com
Neumora Therapeutics advances pipeline for brain penetrant therapies in neurodegenerative and neuropsychiatric disease - Traders Union
NMRA SEC FilingsNeumora Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neumora Therapeutics commits to accelerating Alzheimer agitation therapies - Traders Union
Neumora Shareholders Approve Directors, Auditor and Executive Pay - The Globe and Mail
Neumora (NMRA) director and 10% owner receives 80,000 stock options at $1.86 - Stock Titan
NMRANeumora Therapeutics Inc. stock news, filings & ratings - Quantisnow
Neumora Therapeutics (NMRA) director granted 80,000 options at $1.86 - Stock Titan
Neumora Therapeutics (NMRA) director granted 80,000 stock options at $1.86 - Stock Titan
Neumora (NASDAQ: NMRA) director receives 80,000 stock options grant - Stock Titan
Neumora Therapeutics (NASDAQ: NMRA) investors approve directors, auditor and annual pay vote - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Analyst Reiterates Buy on Neumora, Maintaining $18 Price Target Ahead of Key KOASTAL-2/3 Depression Readouts - TipRanks
Number of shareholders of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
Neumora Therapeutics (NMRA) Edges Lower as Stock Tests Key Support at $1.75Debt Free Companies - newsline.com
Neumora Therapeutics (NMRA) Slides 2.16% as Stock Tests Key Support LevelsRetail Driven Moves - The Legal Advocate
Neumora Therapeutics (NMRA) Holds Steady at $1.85 Amid Mixed SentimentWyckoff Upthrust - The Legal Advocate
Neumora Therapeutics (NMRA) Holds Steady at $1.85 as Consolidation ContinuesDividend Arbitrage - The Legal Advocate
NMRA Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline in Pre-Revenue PhaseEBITDA Margin Trends - The Legal Advocate
Neumora Therapeutics (NMRA): Stock Holds Steady at $1.85 as Key Support and Resistance Levels TightenIV Crush Alert - The Legal Advocate
NMRA Q1 2026 Earnings: Narrower-than-Expected Loss Reflects Disciplined SpendingEarnings Revision Report - newsline.com
Neumora Therapeutics (NMRA) Holds Steady at $1.85 as Stock Navigates Tight RangeTrader Community Signals - Newser
NMRA Q1 2026 Earnings: Narrower-than-Expected Loss Reflects Operational DisciplineLow Growth Earnings - Newser
Neumora’s NMRA-323511 Alzheimer’s Agitation Study Reaches Completion, Setting Up the Next Investor Catalyst - TipRanks
Neumora tops Q4 earnings forecasts as pipeline advances, shares slip - MSN
K2HV Equity reports 5.79M conversion shares for Neumora (NMRA) - Stock Titan
Neumora Therapeutics gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target - TipRanks
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Neumora Therapeutics Inc (NMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Neumora Therapeutics Inc 주식 (NMRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pinto Joshua | President |
Feb 17 '26 |
Sale |
3.54 |
5,967 |
21,093 |
57,783 |
| BERNS PAUL L | See Remarks |
Feb 17 '26 |
Sale |
3.51 |
9,819 |
34,459 |
7,395,185 |
| Milligan Michael Lee | See Remarks |
Feb 17 '26 |
Sale |
3.56 |
1,436 |
5,119 |
21,034 |
0.73%
7.23%
자본화:
|
볼륨(24시간):